Vaxart, Inc. (VXRT)

NASDAQ: VXRT · IEX Real-Time Price · USD
1.30
+0.13 (11.11%)
At close: Dec 2, 2022 4:00 PM
1.32
+0.02 (1.46%)
After-hours: Dec 2, 2022 7:59 PM EST
11.11%
Market Cap 153.56M
Revenue (ttm) 159,000
Net Income (ttm) -104.60M
Shares Out 126.89M
EPS (ttm) -0.64
PE Ratio n/a
Forward PE 42.74
Dividend n/a
Ex-Dividend Date n/a
Volume 3,840,657
Open 1.17
Previous Close 1.17
Day's Range 1.15 - 1.3
52-Week Range 1.11 - 7.61
Beta 0.79
Analysts Buy
Price Target 7.91 (+508.5%)
Earnings Date Nov 8, 2022

About VXRT

Vaxart, Inc., a clinical-stage biotechnology company, engages in the discovery and development of oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, an oral tablet vaccine, which is in a Phase Ib clinical trial with bivalent oral tablet vaccine for the GI.1 and GII.4 norovirus strains; seasonal influenza vaccine, which is in Phase II clinical trial for the treatment of H1 influenza infection; respiratory syncytial virus vaccine; and coronavirus vaccine, wh... [Read more]

Industry Biotechnology
Employees 110
Stock Exchange NASDAQ
Ticker Symbol VXRT
Full Company Profile

Financial Performance

In 2021, Vaxart's revenue was $892,000, a decrease of -77.95% compared to the previous year's $4.05 million. Losses were -$70.47 million, 118.7% more than in 2020.

Financial Statements

Analyst Forecast

According to 10 analysts, the average rating for VXRT stock is "Buy." The 12-month stock price forecast is 7.91, which is an increase of 508.46% from the latest price.

Price Target
$7.91
(508.46% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Vaxart to Present at World Vaccine & Immunotherapy Congress West Coast 2022 on November 29

SOUTH SAN FRANCISCO, Calif., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced that Dr. Sean Tucker, Founder and Chief Scientific Officer, will present at the World Vaccine &...

1 week ago - GlobeNewsWire

VAXART, INC. (VXRT) Reports Q3 Loss, Misses Revenue Estimates

VAXART, INC. (VXRT) delivered earnings and revenue surprises of 4.17% and 100%, respectively, for the quarter ended September 2022.

3 weeks ago - Zacks Investment Research

Vaxart Provides Business Update and Reports Third Quarter 2022 Financial Results

Growing body of clinical evidence supports transformational potential of Vaxart's oral vaccine platform

3 weeks ago - GlobeNewsWire

VAXART, INC. (VXRT) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

VAXART, INC. (VXRT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report.

1 month ago - Zacks Investment Research

3 Supercharged Growth Stocks With 257% to 379% Upside, According to Wall Street

Select analysts believe these industry game changers can skyrocket over the next year.

Other symbols: NIOPLUG
1 month ago - The Motley Fool

Vaxart to Host Third Quarter 2022 Business Update and Financial Results Conference Call on November 8

Conference call to begin at 4:30 p.m. ET

1 month ago - GlobeNewsWire

Vaxart to Present at World Vaccine Congress Europe 2022 on October 13

SOUTH SAN FRANCISCO, Calif., Oct. 10, 2022 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced that Dr. Sean Tucker, Founder and Chief Scientific Officer, and Dr. James Cummings, Chief Medic...

1 month ago - GlobeNewsWire

2 Struggling Stocks to Avoid Right Now

Investors looking for bargains should look elsewhere.

Other symbols: CGC
2 months ago - The Motley Fool

Vaxart Announces Positive Top-line Phase II Clinical Study Data Demonstrating Safety and Immunogenicity of Its Wuhan ...

— Study met primary safety and secondary immunogenicity endpoints —

3 months ago - GlobeNewsWire

Vaxart to Host Conference Call on September 1 at 8:30 AM ET to Discuss Top-line Results from Its Phase II COVID-19 Trial

SOUTH SAN FRANCISCO, Calif., Aug. 31, 2022 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced it will release top-line data from the first part of its planned two-part COVID-19 Phase II tri...

3 months ago - GlobeNewsWire

Vaxart Names Biotech Veteran Ray Stapleton Chief Technology Officer

Dr. Stapleton has more than 20 years of industry experience leading technical, quality and manufacturing operations at commercial and clinical stage biopharmaceutical companies

3 months ago - GlobeNewsWire

Vaxart Announces Highly Regarded Biotech Executive Elaine J. Heron, Ph.D.

Dr. Heron brings decades of experience in executive leadership and life sciences research and development to Vaxart's Board Dr. Heron brings decades of experience in executive leadership and life scienc...

3 months ago - GlobeNewsWire

VAXART, INC. (VXRT) Reports Q2 Loss, Lags Revenue Estimates

VAXART, INC. (VXRT) delivered earnings and revenue surprises of -9.52% and 100%, respectively, for the quarter ended June 2022.

3 months ago - Zacks Investment Research

Vaxart Provides Business Update and Reports Second Quarter 2022 Financial Results

Top-line data from COVID-19 Phase II study expected in the third quarter of 2022

3 months ago - GlobeNewsWire

Vaxart Appoints W. Mark Watson to its Board of Directors

Non-executive director to bring extensive life science industry and finance experience

3 months ago - GlobeNewsWire

Vaxart Stockholders Approve Proxy Proposals 2, 3 and 4

All six proposals approved in the 2022 Proxy Statement

3 months ago - GlobeNewsWire

Could This Unknown Stock Beat Moderna in 2023?

Vaxart is still in the coronavirus vaccine race, even though its competitors remain very far ahead.

4 months ago - The Motley Fool

Vaxart to Host Second Quarter 2022 Business Update and Financial Results Conference Call on August 8

Conference call to begin at 4:30 p.m. ET Conference call to begin at 4:30 p.m. ET

4 months ago - GlobeNewsWire

Vaxart Provides New Update on Proxy Voting and Urges All Stockholders of Record as of April 11, 2022, to Vote by Augu...

Key Proposal #2 Needs an Additional 0.9% of Outstanding Shares Votes to Pass

4 months ago - GlobeNewsWire

Vaxart Publishes Clinical Data Suggesting its Oral COVID-19 Pill Vaccine Candidate Induces Long-Lasting Mucosal Immun...

Vaccine-induced mucosal IgA antibody responses persisted for up to 1 year and had a higher neutralizing activity compared with convalescent samples

4 months ago - GlobeNewsWire

Vaxart to Present Preclinical and Clinical Data From Its COVID-19 Oral Tablet Vaccine Program at ICMI 2022

SOUTH SAN FRANCISCO, Calif., July 14, 2022 (GLOBE NEWSWIRE) --  Vaxart, Inc. (Nasdaq: VXRT) today announced that Dr. Sean Tucker, SVP and Chief Scientific Officer, and Dr. Rebecca Flitter, Senior Scient...

4 months ago - GlobeNewsWire

Vaxart Provides an Update on Proxy Voting and Urges All Stockholders of Record as of April 11, 2022 to Vote by July 5...

Key Proposal #2 has received significant support, but additional votes are needed for approval

5 months ago - GlobeNewsWire

Vaxart Announces Agreement with hVIVO to Develop World's First Human Omicron Challenge Model

Model will be used in Vaxart's Phase II Omicron Challenge Trial

5 months ago - GlobeNewsWire

Vaxart to Host Investor Q&A Webcast

Management to discuss progress on its programs, annual stockholders' meeting proposals

5 months ago - GlobeNewsWire

What Could a Recession Mean for Healthcare Stocks?

It depends on which subsector you're talking about.

Other symbols: AZNGSKNVSSNY
5 months ago - The Motley Fool